Introduction/Overview
Erucic acid (CAS number: 112-86-7) is a long-chain monounsaturated fatty acid with a chemical structure of 22 carbon atoms and an omega-9 fatty acid. It has a cis double bond and belongs to the monounsaturated fatty acid (MUFA) family. Originally isolated from radish (Brassica rapa) seeds, erucic acid has attracted widespread attention in the field of natural product pharmacology in recent years due to its unique biological activity and pharmacological potential. Especially in terms of neuroprotection and cognitive function improvement, erucic acid has shown significant therapeutic effects and has become a potential candidate compound for studying the prevention and treatment of neurodegenerative diseases such as Alzheimer's disease (AD) and other dementia.
This review aims to systematically summarize the chemical structure and physicochemical properties, plant sources and extraction methods, pharmacological activities and mechanisms of action of erucic acid, with a focus on exploring its molecular targets and pharmacological evaluation in the field of neuroprotection. Finally, it looks forward to its clinical application prospects, providing theoretical basis and reference for subsequent research and drug development.
Chemical structure and physicochemical properties
The chemical name of erucic acid is cis-13 Docosenoic acid, with a molecular formula of C22H42O2 and a molecular weight of 338.5760. Its structural feature is a long-chain fatty acid with 22 carbon atoms, containing a cis double bond (C13=C14) located at the 13th carbon atom. This long-chain structure endows erucic acid with high hydrophobicity and lipid solubility, with a LogP value of up to 9.1764, indicating its extremely strong lipid solubility characteristics.
In terms of physical and chemical properties, the polar surface area (TPSA) of erucic acid is only 37.3 Å ², and its water solubility is extremely low (0.0006 mg/mL), which is consistent with the structural characteristics of its long-chain fatty acids. Despite its poor water solubility, erucic acid can efficiently cross the blood-brain barrier (BBB), laying the foundation for its pharmacological effects on the nervous system. In addition, erucic acid does not exhibit hERG channel inhibition and the Ames mutagenicity test result is 0, indicating its high safety and low toxicological risk.
Plant sources and extraction methods
Mustard acid is mainly present in the seed oil of cruciferous plants, especially in plants such as radish (Brassica rapa), mustard (Brassica juncea), and mustard oil (Eruca sativa). Carrot seed oil has a high content of erucic acid, usually up to 30% -50%. These vegetable oils are the main source of industrial and medicinal erucic acid.
The extraction methods usually use solvent extraction and cold pressing techniques. Solvent extraction is commonly carried out using organic solvents such as hexane or ether at room or low temperatures to avoid oxidative degradation of fatty acids. After extraction, high-purity erucic acid is obtained through distillation and chromatographic purification techniques. In recent years, supercritical CO2 extraction technology has been widely used for the extraction of erucic acid due to its environmental protection, high efficiency, and low-temperature advantages, which can maximize its biological activity.
Pharmacological activity research
As a natural monounsaturated fatty acid, erucic acid has pharmacological activities mainly focused on neuroprotection and cognitive function improvement. Numerous in vitro and in vivo experiments have shown that erucic acid can regulate the metabolism of long-chain fatty acids in the brain, restore the balance of fatty acids, and thereby improve neurological dysfunction.
-
Neuroprotective effect
Mustard acid can significantly inhibit neuronal apoptosis, reduce oxidative stress, alleviate inflammatory reactions, and thus protect neurons from damage. For example, erucic acid regulates the expression of BCL2 family proteins, inhibits the activity of apoptosis related enzyme CASP3, and reduces neuronal cell death.
-
Improvement of cognitive function
Animal model studies have shown that intake of erucic acid can improve memory impairment and decreased learning ability, and delay cognitive decline. The mechanism involves regulating the activity of neurotransmitter enzymes such as acetylcholinesterase (ACHE) and enhancing neuronal signaling.
-
Anti dementia potential
Mustard acid reduces the accumulation of β - amyloid protein and slows down neurodegenerative changes by regulating the expression of Alzheimer's disease-related protein APP and β - secretase BACE1. In addition, erucic acid also affects the phosphorylation status of microtubule associated protein MAPT (tau protein), preventing the formation of neurofibrillary tangles.
-
Anti inflammatory and antioxidant properties
Mustard acid activates the nuclear factor erythroid 2-related factor 2 (NRF2) pathway, enhances cellular antioxidant capacity, reduces inflammatory factor expression, and alleviates neuroinflammatory responses.
In summary, erucic acid exerts multi-target and multi pathway protective effects in various neurodegenerative pathological processes, demonstrating its enormous potential as a neuroprotective agent.
Mechanism of action and molecular targets
The neuroprotective effect of erucic acid involves multiple key molecular targets, and the specific mechanism of action is as follows:
-
BCL2 (anti apoptotic protein)
Mustard acid upregulates BCL2 expression, enhances cell anti apoptotic ability, and prevents programmed cell death of neurons due to endogenous or exogenous stimuli.
-
APP (amyloid precursor protein) and BACE1 (β - secretase)
By inhibiting BACE1 activity, erucic acid reduces abnormal APP cleavage, lowers the production of β - amyloid protein, and alleviates amyloid plaque deposition, which is a key step in preventing and treating Alzheimer's disease.
-
MAPT (microtubule associated protein Tau)
Mustard acid regulates the phosphorylation status of tau protein, prevents its abnormal aggregation, slows down the formation of neurofibrillary tangles, and protects neuronal structure and function.
-
SIRT1 (deacetylase)
Mustard acid activates SIRT1, promotes cellular metabolic homeostasis and antioxidant response, delays cellular aging process, and enhances the repair ability of the nervous system.
-
MAPK1 (mitogen activated protein kinase)
By regulating the MAPK signaling pathway, erucic acid regulates cell proliferation, differentiation, and stress response, participating in neuroprotection and regeneration.
-
ACHE (Acetylcholinesterase)
Mustard acid inhibits ACHE activity, increases acetylcholine concentration, improves neural transmission, and enhances cognitive function.
-
CASP3 (Caspase 3)
Inhibit CASP3 activity, reduce cell apoptosis, and protect neuronal survival.
-
SNCA (alpha synuclein)
Mustard acid regulates the expression and aggregation of alpha synuclein, preventing pathological changes related to neurodegenerative diseases such as Parkinson's disease.
-
NRF2 (antioxidant transcription factor)
Activate the NRF2 pathway, enhance antioxidant gene expression, and alleviate oxidative stress damage.
Through the synergistic effect of multiple targets mentioned above, erucic acid effectively regulates the living environment of nerve cells, maintains the homeostasis of the nervous system, and exerts significant neuroprotective effects.
Evaluation of drug properties and pharmacokinetics
The pharmacological evaluation of erucic acid shows that it has certain advantages and challenges:
-
Pharmacokinetic characteristics
The high molecular weight of erucic acid (338.5760) and its extremely high lipid solubility (LogP 9.1764) make it easy to cross the blood-brain barrier, ensuring its effective concentration in the central nervous system. Low polarity and small TPSA values contribute to its passive diffusion into brain tissue.
-
safety
Mustard acid does not exhibit hERG channel inhibition, reducing the risk of cardiac toxicity. The Ames test is negative, indicating no significant mutagenicity and good safety.
-
Water solubility and bioavailability
The extremely low water solubility (0.0006 mg/mL) limits its oral absorption and in vivo distribution, and may require the use of liposomes, nanoparticles, or other drug delivery systems to improve bioavailability.
-
metabolic pathway
Mustard acid is mainly metabolized through β - oxidation in the body to generate energy. The impact of its metabolites on the nervous system still requires further research.
-
Drug interactions
Due to its lipid solubility and metabolic characteristics, erucic acid may have competitive metabolism with other lipid soluble drugs, and potential drug interaction risks need to be considered.
In summary, erucic acid has good central nervous system penetration ability and safety, but poor water solubility and low bioavailability are the main technical bottlenecks that need to be overcome in its pharmaceutical process.
Clinical application prospects and prospects
As a natural monounsaturated fatty acid, erucic acid has shown broad application prospects in the fields of neuroprotection and cognitive impairment treatment. Currently, there are limited treatment options for Alzheimer's disease, Parkinson's disease, and other neurodegenerative diseases. Akutamic acid, with its multi-target regulatory mechanism and good blood-brain barrier penetration, is expected to become a novel neuroprotective agent.
Future research directions include:
-
Deepening preclinical research
Systematically evaluate the efficacy and safety of erucic acid in different neurodegenerative disease models, clarify the dose-response relationship and long-term medication effects.
-
Drug formulation innovation
Develop water-soluble improved dosage forms, such as nanocarriers, liposomes, or solid dispersions, to enhance the bioavailability and targeting of erucic acid.
-
Expansion of Mechanism Research
Thoroughly analyze the molecular network of erucic acid regulating neuronal metabolism, inflammation, and apoptosis, and explore potential synergistic targets.
-
Clinical trial design
Based on sufficient preclinical data, initiate early clinical trials to evaluate the safety and efficacy of erucic acid in patients with cognitive impairment.
-
Combination therapy strategy
Explore the combined application of erucic acid and existing neuroprotective drugs to achieve synergistic effects and improve treatment efficacy.
In summary, erucic acid, as a natural fatty acid with unique neuroprotective effects, has the potential to become a new drug for the treatment of neurodegenerative diseases and deserves further in-depth research and development.
Conclusion
As a natural monounsaturated fatty acid derived from radish seeds, erucic acid has demonstrated unique advantages in the prevention and treatment of cognitive impairment and neurodegenerative diseases due to its excellent blood-brain barrier penetration ability and multi-target neuroprotective mechanism. It slows down neuronal apoptosis, inhibits amyloid deposition, enhances antioxidant and anti-inflammatory responses by regulating key molecules such as BCL2, APP, BACE1, MAPT, SIRT1, etc., providing new ideas for the treatment of neurological diseases.
Although the poor water solubility and low bioavailability of erucic acid limit its direct application, with the improvement of modern pharmaceutical methods and in-depth preclinical research, it is expected to overcome these bottlenecks and achieve its clinical translation. In the future, erucic acid is expected to become an important neuroprotective agent in the field of natural product pharmacology, bringing new treatment options for patients with neurodegenerative diseases.
In summary, as an important member of natural products, erucic acid has good pharmacological activity and potential for drug development, and deserves continuous attention and investment in basic research and clinical development.
